At what pace is the antifungals market growing, and what is its estimated value?
The antifungals market size has grown strongly in recent years. It will grow from $27.01 billion in 2024 to $29.67 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to fungal disease prevalence, aging population, healthcare infrastructure, awareness and education.
The antifungals market size is expected to see strong growth in the next few years. It will grow to $41.84 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to emerging fungal strains, regulatory approvals, global health concerns, increased healthcare spending, patient education and awareness. Major trends in the forecast period include research and development, telemedicine and e-health, advancements in antifungal drug development, collaborations and partnerships.
Get Your Free Sample of The Global Antifungals Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp
What are the top drivers to the rising demand in the antifungals market?
The increasing prevalence of fungal infections is expected to propel the growth of the antifungals market going forward. Fungal infections are diseases caused by the invasion and growth of fungi in or on the body. Fungi can affect various parts of the body, including the skin, nails, lungs, and mucous membranes. The increasing prevalence of fungal infections is due to factors such as the rising number of immunocompromised individuals, climate change creating more favorable environments for fungal growth, increased use of broad-spectrum antibiotics disrupting natural microbiomes, poor hygiene, urbanization, and the growing incidence of chronic conditions like diabetes that predispose individuals to fungal infections. Antifungals play a crucial role in treating fungal diseases by inhibiting the growth and reproduction of fungi, either by disrupting their cell wall or membrane, blocking essential enzymatic processes, or interfering with their ability to synthesize vital components, thereby reducing fungal load, alleviating symptoms, and preventing the spread of infection within the body. For instance, in September 2024, according to the International Society For Infectious Diseases, a US-based non-profit organization, an annual incidence of 6.5 million invasive fungal infections, associated with approximately 3.8 million mortalities, of which 2.5 million (68%; range 35-90%) are directly attributable to these infections. Therefore, the increasing incidence of fungal infections is expected to drive the antifungals market.
How is the antifungals market segmented?
The antifungals market covered in this report is segmented –
1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines
2) By Route of Administration: Oral, Parenteral, Topical
3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users
Subsegments
1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin
2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole
3) By Polyenes: Amphotericin B, Nystatin
4) By Allylamines: Terbinafine, Naftifine
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report
Who are the top competitors in the antifungals market?
Major companies operating in the antifungals market include Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited
What significant trends should we anticipate in the antifungals market over the forecast period?
Drug developers and manufacturers are scaling up the various departments such as research and development, marketing, and manufacturing through collaborations and strategic partnerships with other companies and research institutes, to expand their product portfolios. So, companies in the anti-infective drugs market should consider strategic collaborations to broaden their scope and product portfolios to increase revenues and stay competitive in the market.
Which regional trends are influencing the antifungals market, and which area dominates the industry?
North America was the largest region in the drugs for antifungals market in 2023. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Antifungals Market Report 2025 Offer?
The antifungals market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
The antifungal drugs refer to drugs that are used to detect and eliminate fungal pathogens. The fungal pathogens thrive in the body in unhygienic and unclean environments. These drugs are also known as antimycotic medications, used to treat and prevent mycoses such as athlete’s foot, ringworm, candidiasis (thrush), and serious systemic infections such as cryptococcal meningitis, and others.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2442
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
